A shortage began with Adderall and spread to Ritalin. A government crackdown made it worse. 

As 2023 began, the national Adderall shortage had spread to other drugs used to treat attention-deficit/hyperactivity disorder (ADHD). Experts expect the mess to continue for much of the year.  

The shortages started with Adderall—known generically as amphetamine mixed salts—which became harder to get because of a surge in demand during the pandemic, coupled with manufacturing bottlenecks.   

The U.S. Food and Drug Administration (FDA) acknowledged the drug shortage last October, saying Teva Pharmaceutical Industries Ltd. (TEVA), the largest Adderall manufacturer, was “experiencing ongoing intermittent manufacturing delays.” Other...

Subscribe or sign in to view the rest of this content

All digital content on this site is FREE!

Sign In